The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).
It handles the millions of daily tasks—translation, tagging, and moderation—that require consistent, repeatable results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results